Advanced Trends in Cellular Therapies for Leukemia and Myeloma

Abstract

This paper aims to critically discuss the current developments, clinical uses, and new trends of cellular therapies to leukemia and multiple myeloma and their mechanisms, therapeutic possibilities, and the challenges. This study has been done as a narrative review by following a systematic search of the published works. Electronic databases such as PubMed, Google Scholar, Science Direct and Springer Link were searched using relevant articles. Articles that were published in 2015, and 2026 were identified. The screening and analysis of data were done rationally to cellular therapies like CAR-T cells, natural killer cells, or T-cell receptor-engineered therapies. Major findings reveal that CAR-T cell therapy has shown a high level of efficiency in the treatment of relapsed and refractory leukemia and multiple myeloma, and a high remission rate. New technologies, such as dual-target CAR-T cells, gene-editing technologies, combination therapies, and so forth, have continued to improve the outcomes of therapies. The study concludes that cellular therapies have important scope in the treatment of hematological malignancies offering tailored and personal treatments. Ongoing studies and technological developments are prerequisite to solve the current issues and become more accessible to obtain better clinical outcomes in the future.